Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68001-0627-27 68001-0627 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan 30, 2025 In Use
43598-0427-37 43598-0427 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 5, 2014 In Use
55111-0496-60 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 10, 2020 In Use
25021-0215-98 25021-0215 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sep 15, 2016 In Use
61703-0319-22 61703-0319 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Nov 22, 1999 In Use
75907-0225-11 75907-0225 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Mar 1, 2025 In Use
16729-0426-05 16729-0426 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug 6, 2018 In Use
68001-0504-54 68001-0504 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jun 11, 2021 In Use
55390-0809-01 55390-0809 Cytarabine Cytarabine Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, subcutaneous, intrathecal Jun 28, 1996 Dec 31, 2010 No Longer Used
31722-0775-12 31722-0775 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 5, 2024 In Use
68180-0738-01 68180-0738 decitabine decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 6, 2019 Jan 1, 2040 In Use
64980-0276-06 64980-0276 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb 1, 2017 In Use
50419-0208-01 50419-0208 Radium Ra 223 dichloride Xofigo 30.0 uCi/mL Chemotherapy Radiopharmaceutical Radium 223 Intravenous May 20, 2013 In Use
00143-9165-01 00143-9165 Denosumab-qbde ENOBY 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
65219-0668-01 65219-0668 Denosumab CONEXXENCE 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 30, 2025 In Use
72606-0037-01 72606-0037 Denosumab-bmwo Stoboclo 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
61314-0228-94 61314-0228 Denosumab WYOST 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 2, 2025 In Use
00143-9166-01 00143-9166 Denosumab-qbde XTRENBO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
71202-0012-10 71202-0012 Denosumab OSPOMYV 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 1, 2025 Oct 31, 2025 In Use
72606-0038-01 72606-0038 Denosumab-bmwo Osenvelt 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
70121-2701-01 70121-2701 Denosumab-mobz Oziltus 70.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Dec 23, 2025 In Use
71202-0012-11 71202-0012 Denosumab OSPOMYV 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 1, 2025 Oct 31, 2025 In Use
83457-0012-10 83457-0012 Denosumab OSPOMYV 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Oct 10, 2025 In Use
55513-0710-21 55513-0710 Denosumab Prolia 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Mar 5, 2024 In Use
83257-0030-11 83257-0030 Denosumab-kyqq AUKELSO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jan 5, 2026 In Use

Found 12250 results — Export these results